Fatty acid amide hydrolase (FAAH) terminates the endocannabinoid signaling pathway that regulates numerous neurobehavioral processes in animals by hydrolyzing a class of lipid mediators, N-acylethanolamines (NAEs). Recent identification of an Arabidopsis FAAH homologue (AtFAAH) and several studies, especially those using AtFAAH overexpressing and knock-out lines suggest that a FAAH-mediated pathway exists in plants for the metabolism of endogenous NAEs. Here, I provide evidence to support this concept by identifying candidate FAAH cDNA sequences in diverse plant species. NAE amidohydrolase assays confirmed that several of the proteins encoded by these cDNAs indeed catalyzed the hydrolysis of NAEs in vitro. Kinetic parameters, inhibition properties, and substrate specificities of the plant FAAH enzymes were very similar to those of mammalian FAAH. Five amino acid residues determined to be important for catalysis by rat FAAH were absolutely conserved within the plant FAAH sequences. Site-directed mutation of each of the five putative catalytic residues in AtFAAH abolished its hydrolytic activity when expressed in Escherichia coli. Contrary to overexpression of native AtFAAH in Arabidopsis that results in enhanced seedling growth, and in seedlings that were insensitive to exogenous NAE, overexpression of the inactive AtFAAH mutants showed no growth enhancement and no NAE tolerance. However, both active and inactive AtFAAH overexpressors displayed hypersensitivity to ABA, suggesting a function of the enzyme independent of its catalytic activity toward NAE substrates. Yeast two-hybrid screening identified Arg/Ser-rich zinc knuckle-containing protein as a candidate protein that physically and domain-specifically interacts with AtFAAH and its T-DNA knock-out Arabidopsis was hypersensitive to ABA to a degree similar to AtFAAH overexpressors. Taken together, AtFAAH appears to have a bifurcating function, via NAE hydrolysis and protein-protein interaction, to control Arabidopsis growth and interaction with phytohormone signaling pathways. These studies help to functionally define the group of enzymes that metabolize NAEs in plants, and further will expand the knowledge-base of lipid metabolism and signaling for manipulation of various physiological processes important to plant growth and responses to environmental stress.

Cannabinoids and cannabinoid receptors have been shown to play important roles in immune regulation particularly as modulators of anti-inflammatory cytokines and antibody production. The predominant cannabinoid receptor involved in this immune regulation is cannabinoid receptor 2 (CB2), which is robustly expressed in B cells. Utilizing a combination of bioinformatics, 5' RACE, real time RT-qPCR, and reporter assays, we showed that human B cells from peripheral blood mononuclear cells (PBMC) expressed one CB2 transcript while mouse B cells from spleen express three CB2 transcripts. Alignment of the sequenced B cell RACE products to either the mouse or human genome, along with the GenBank mRNA sequences, revealed that the transcripts isolated in this study contained previously unidentified transcriptional start sites (TSSs). In addition, expression construct testing of the genomic region containing the TSSs of the mouse CB2 exon 1 and 2 transcripts showed a significant increase of promoter activity. Bioinformatics analysis for cis-sequences in the promoter regions identified DNA binding sites for NF-kB, STAT6, and Elk1 transcription factors activated by LPS, IL-4 and anti-CD40. Regarding variations in CB2 transcript expression among the immune cell subtypes, RACE analysis showed that the exon 1b transcript is seen in B cells but not in T cells, dendritic cells or macrophages. Furthermore, RT-qPCR showed variations in transcript expression during B cell development as well as in resting versus LPS or IL-4/anti-CD40 stimulated B cells. The exon 1a transcript was predominant in pre-, immature and resting B cells whereas the exon 1b and 2 transcripts were enhanced in mature and activated B cells. These data showed for the first time that human B cells use one TSS for CB2 expression while mouse B cells use multiple TSSs for the expression of three CB2 transcripts, in which the expression of the individual transcript is related to immune cell type and/or cell activation state. Additionally, this is the first report in mouse B cells defining TSSs that are in genomic areas with promoter activity thus suggesting the location of two promoter regions. Defining the CB2 transcript expression during various stages of B cell activation provide clues to therapeutic methods.

La présence du système endocannabinoïde (eCB), en particulier le récepteur CB1 (CB1R), dans la rétine, le corps genouillé latéral, et l’aire visuelle primaire (V1) du singe a récemment été mise en évidence. Cependant, aucune étude n’a démontré la présence de ce système dans l’aire visuelle secondaire V2, une région qui reçoit la plupart des efférences de V1. Comme V1 exprime ce récepteur, nous faisons l’hypothèse que l’aire V2 l’exprime également. Le but de notre étude est donc de caractériser l’expression et la localisation cellulaire de ce système dans l’aire V2 du singe vervet. Des cerveaux de cinq singes vervets (Chlorocebus sabeus) adultes ont été utilisés. Les marqueurs cellulaires NeuN, SMI-32, et PV ont été employés pour caractériser et identifier les différentes couches de V2. En localisant ces derniers, nous déterminons la distribution de CB1R et des enzymes de synthèse (NAPE-PLD) et de dégradation (FAAH) du système eCB en utilisant des techniques d’immunofluorescence. De plus, l’organisation laminaire en six couches de V2 a été mise en évidence par nos marqueurs cellulaires. Nos résultats démontrent la présence de CB1R dans les fibres axonales aux extrémités de V2, c’est-à-dire dans les couches superficielles (1-3) et profondes (5-6). CB1R est peu ou pas exprimé dans la couche 4. CB1R entoure, mais n’est pas exprimé par les cellules positives- NeuN, SMI-32 et PV. Cependant, les enzymes NAPE-PLD et FAAH sont présentes dans les cellules pyramidales SMI-32 et les cellules interneurones PV -positives. Ces données indiquent que CB1R, NAPE-PLD et FAAH sont présentes dans V2 et pourraient moduler l’information visuelle provenant de V1 et se dirigeant vers les aires V4 et V5, et probablement, influencer la perception visuelle. / The presence of the endocannabinoid system in the retina, the lateral geniculate body, and the primary visual area (V1) of the monkey has recently been established. However, no study has demonstrated the presence of this system in area V2, a region that receives most of the afferents from V1. As V1 expresses this system, we assume that the area V2 also expresses it. The aim of our study is to characterize the expression and cellular localization of this system in the visual cortex V2 of the vervet monkey. The brains of 5 adult monkeys were used in this project. Cellular markers NeuN, SMI-32, and PV were used to characterize and identify the layers of V2. Using immunofluorescence, these markers were also localized in order to study the distribution of CB1R, the enzyme of synthesis (NAPE-PLD) and of degradation (FAAH) of eCB ligands. The six-layer organization of V2 was also identified by our cellular markers. Our results show the presence of the eCB system in area V2. Furthermore, we found that CB1R immunoreactivity is present in the axonal fibers at the ends of V2; in the superficial (L1-3) and deep (L5-6) layers. CB1R expression was low to non-existence in layer 4. CB1R surrounds but does not co-localize with NeuN-, SMI-32-, and PV- positive cells. On the other hand, NAPE-PLD and FAAH enzymes were co-localized with SMI-32-positive pyramidal cells and PV-positive interneuron cells. These data, therefore, indicate that CB1R, NAPE-PLD and FAAH are present in V2 and their presence can modulate visual information coming from V1 and going to V4 and V5, and probably, influence visual perception.

Adults exhibit significant differences in drug vulnerability, learning ability, and emotive processing than adolescents. Long-lasting synaptic changes, including long-term depression (LTD), can endure many hours and are believed to be key to encoding memories and persistent cognitive changes such as addiction. The ventral tegmental area (VTA) is the primary source of midbrain dopamine (DA) and is regulated by local inhibitory GABA neurons. GABA regulation can decrease, resulting in dis-inhibition of DA neurons and increased feelings of reward, learning, or salience attachment to memories. Endocannabinoids (eCBs) are signaling molecules that often result in synaptic plasticity changes, and the eCB system has shown pronounced cross-talk with opioid signaling and receptor pathways. We examined eCB mediated plasticity of excitatory inputs to GABA neurons within the VTA and how THC, opioids, and age influence this plasticity. We determined that direct CB1 receptor activation in the mouse results in reduced excitatory input activity to GABA, resulting in GABA depression. CB1-mediated GABA depression was lost following chronic exposure to THC, suggesting THC injection has already activated this pathway. Chronic THC occlusion of GABA LTD was then reversible following a week of drug withdrawal. Next, as adult animals tend to exhibit reduced emotive influence, learning, and drug affect when compared to adolescents we examined if LTD of VTA GABA neurons was present in adults. We determined that adult mice no longer undergo HFS-induced LTD. Interestingly, the eCB pathway is still active, as we determined that both CB1 receptor activation and mGluR5 activation still results in GABA depression in adults. We then determined that a greater electrical HFS could induce LTD of excitatory inputs to adult VTA GABA neurons, suggesting a change in adults leading to an increase in induction thresholds for GABA plasticity. Morphine was found to induce similar LTD of GABA neurons through the mu-opioid receptor in both adolescents and adults. This LTD is likely pre-synaptic, similar to THC induced LTD, and is potentially mediated through the same presynaptic pathways as CB1-dependent LTD as injection of either THC or morphine eliminates depression by the other. Chronic morphine injection eliminates HFS-induced LTD in adolescents but only results in a loss of LTD in 58% of adult experiments suggesting resistance to morphine exposure at this synapse in adults. In summary, THC and morphine appear to act pre-synaptically to induce GABA LTD within the VTA and occlude further LTD by the other drug. Additionally, development into adulthood significantly alters the propensity of GABA neurons to undergo plasticity and greater levels of stimulus are required to elicit lasting changes.

No description available.

Activation of the CB1 receptor is modulated by aspartate residue D2.63176 in transmembrane helix (TMH) II. Interestingly, D2.63 does not affect the affinity for ligand binding at the CB1 receptor. Studies in class A GPCRs have suggested an ionic interaction between residues of TMHII and VII. In this report, modeling studies identified residue K373, in the extracellular (EC)-3 loop, in charged interactions with D2.63. We investigated this possibility by performing reciprocal mutations and biochemical studies. D2.63176A, K373A, D2.63176A-K373A, and the reciprocal mutant with the interacting residues juxtaposed, D2.63176K-K373D were characterized using radioligand binding and guanosine 5'-3-O-(thio)triphosphate functional assays. None of the mutations resulted in a significant change in the binding affinity of CP55,940 or SR141716A. Computational results indicate that the D2.63176-K373 ionic interaction strongly influences the conformation(s) of the EC-3 loop, providing a structure-based rationale for the importance of the EC-3 loop to signal transduction in CB1. Specifically, the putative ionic interaction results in the EC-3 loop pulling over the top (extracellular side) of the receptor; this EC-3 loop conformation may serve protective and mechanistic roles. These results suggest that the ionic interaction between D2.63176 and K373 is crucial for CB1 signal transduction. This work may help to aide drug design efforts for the effective treatment of different diseases. The cannabinoid receptors of osteoblasts may represent a target for the treatment of bone disorders such as osteoporosis. Our research demonstrates that cannabinoids can affect important signaling molecules in osteoblasts. In MC3T3-E1 osteoblastic cells, the CB1 antagonist, AM251, has been reported to induce increases in Runx2 mRNA, mineralized bone nodule formation, and activation of signaling molecules such as ERK and AKT (Wu et al., 2011). Studies from our lab characterizing mice in which both CB1 and CB2 receptors were inactivated by homologous recombination have demonstrated increased bone mass coupled with enhanced osteoblast differentiation of bone marrow stromal cells in culture (manuscript in preparation). We explored the effect of antagonizing CB1 and CB2 cannabinoid receptors in osteoblastic cells to gain insights into molecular pathways that may help to explain the effects of the endocannabinoid system (ECS) in bone development. Our data was generated by running time course experiments with MC3T3-E1 cells under the influence of SR141716A, SR144528 or both in combination. The cells were harvested with a lysis buffer at specific time points and analyzed by western blot analysis. Quantification of protein activation was calculated using LiCor imaging equipment and software. Within 15 minutes, treatment with the CB1 receptor antagonist SR141716A resulted in several fold increases in pERK, pSMAD158, and pAKT. SR144528, a CB2 receptor antagonist, caused increases in pERK and pSMAD158, but not pAKT. When both antagonists were applied together, pERK and pSMAD158 levels increased, while pAKT signaling was diminished compared to SR141716A alone. The finding that cannabinoid receptor antagonists alter the activity of the SMAD158 complex is a novel finding, which suggests that cannabinoids can influence bone morphogenic signaling pathways, and therefore play a significant role in osteoblast differentiation and function. / Cell Biology

Le système endocannabinoïde (eCB) est présent dans le système nerveux central (SNC) de mammifères, incluant la rétine, et est responsable de la régulation de nombreux processus physiologiques. Bien que la présence du récepteur cannabinoïde de type 1 (CB1R) a bien été documenté dans la rétine de rongeurs et primates, il y a encore une controverse quant à la présence du récepteur cannabinoïde de type 2 (CB2R) au niveau du SNC. En utilisant la microscopie confocale, nous sommes les premiers à signaler les patrons d’expression du CB2R dans la rétine de singe. Nos résultats démontrent que le CB2R est exprimé exclusivement dans les cellules de Müller de la rétine du singe. En outre, nous avons comparé les différents patrons d’expression du système eCB dans la rétine de la souris, du toupaye, ainsi que du singe vervet et macaque. Nous rapportons que les distributions de CB1R, FAAH (fatty acid amid hydrolase), MAGL (monoacylglycerol lipase) et DAGLα (diacylglycerol lipase alpha) sont hautement conservées parmi ces espèces alors que CB2R et NAPE-PLD (N-acyl phosphatidylethanolamine phospholipase D) présentent différents profils d'expression. CB2R n'a pas été détecté dans les cellules neuronales de la rétine des primates. L’immunoréactivité de NAPE-PLD est présente dans les couches de la rétine de souris et toupayes, mais a été limitée à la couche des photorécepteurs des singes vervet et macaque. Pour étudier les corrélats neuronaux et le rôle de la signalisation du système eCB dans la rétine, nous avons établi un protocole standard pour l'électrorétinographie (ERG), puis enregistré la réponse ERG de la rétine après le blocage des récepteurs avec des antagonistes spécifiques pour CB1R (AM251) et CB2R (AM630). Comparé au témoin, dans des conditions photopiques, et à certaines intensités faibles du stimulus, le blocage de CB1R diminue l'amplitude de l'onde-b, alors qu’à des intensités plus élevées, le blocage de CB2R augmente l'amplitude des deux-ondes a et b. De plus, le blocage des récepteurs cannabinoïdes provoque une augmentation de la latence des deux ondes a et b. Dans des conditions d’adaptation à l'obscurité, le blocage de CB1R et CB2R réduit l’amplitudes de l'onde a seulement à des intensités plus élevées et réduit l’onde b à intensités plus faibles. Des augmentations significatives de latence ont été observées dans les deux cas. Ces résultats indiquent que les récepteurs CB1 et CB2 chez les primates non humains sont impliqués dans la fonction rétinienne conditions photopiques. En outre, nous avons évalué le profil d'expression du CB1R, de FAAH et de NAPE-PLD au-delà de la rétine dans le corps géniculé latéral des singes et nous rapportons pour la première fois que CB1R et FAAH sont exprimés davantage dans les couches magnocellulaires. La NAPE-PLD a été localisée à travers les couches magno- et parvocellulaires. Aucune de ces composantes n’est exprimée dans les couches koniocellulaires. Ces résultats nous aident à mieux comprendre les effets des cannabinoïdes sur le système visuel qui pourraient nous mener à trouver éventuellement de nouvelles cibles thérapeutiques. / The endocannabinoid (eCB) system is present in the mammalian central nervous system, including the retina, and is responsible for the regulation of many physiological processes. Anatomical and functional data collected in the retina indicate that cannabinoid receptors are important mediators of retinal function. Although the presence of the cannabinoid receptor type 1 (CB1R) has been documented in the rodent and primate retina, there is still some controversy regarding the presence of the CB2 receptor (CB2R) within the central nervous system. By using confocal microscopy, we are the first to report the distribution patterns of CB2R in the monkey retina. Our results show that CB2R is expressed exclusively in the Müller cells of the primate retina. Furthermore, we compared the eCB system distribution patterns in the retinas of mice, tree shrews, and vervet and macaque monkeys. We report that CB1R, FAAH, MAGL, and DAGLα distributions are highly conserved among these 3 species whereas CB2R and NAPE-PLD exhibit different expression patterns. CB2R was not detected in the neuroretinal cells of primates. NAPE-PLD immunoreactivity was present in the retinal layers of mice and tree shrews but was restricted to the photoreceptor layer in both species of primates studied. To study the neural correlates and the role of eCB signaling in the retina, we first established a standard protocol for electroretinography (ERG) and then recorded the ERG response of the retina after blocking receptors with specific antagonists for CB1R (AM251) and CB2R (AM630). Compare to control, in photopic conditions, at certain low flash intensities, only the blockade of CB1R decreases the amplitude of the a-wave and b-wave, while at some high flash intensities, blockade of CB2R increase the amplitude of both a- and b-waves. Also the blockade of the cannabinoid receptors causes an increase in the latency of both a- and b-waves. In dark-adapted eyes, blockade of the CB1R and CB2R reduces the a-wave only amplitudes in the higher intensities and decrease the b-wave in lower intensities. Some significant increases in latency were observed in both cases. These results indicate that CB1 and CB2 receptors in primates are involved in retinal function under photopic and scotopic conditions. In addition, we assessed the expression pattern of eCB components CB1R, FAAH, and NAPE-PLD beyond the retina in the dorsal lateral geniculate nucleus (dLGN) of primates and report for the first time that while CB1R and FAAH are more abundantly expressed in the magnocellular layer, NAPE-PLD is distributed throughout both the magno- and parvocellular layers. None of these components are expressed in the koniocellular layer. These findings augment our understanding of the effects of cannabinoids on the visual system and may lead to novel therapeutics targeted to eCB signaling.

Our project was aimed at the development of novel CB1 cannabinoid receptor antagonists that may have clinical applications for the treatment of cannabinoid and psychostimulant addiction. In this study, we designed, synthesized, and established the CB1 affinity for the 1,5-diaryl-1,2,3- triazole esters, a series of 4,5-diaryl-1-substituted-1,2,3-triazole analogues and a series of 4,5- diaryl-2-substituted-1,2,3-triazoles. Our research group has been interested in the synthesis of amphibian alkaloids due to their interesting biological activities. We have recently developed a general synthetic strategy which can rapidly prepare a few amphibian alkaloids simply from the abundant natural product (-)- cocaine This strategy was first successfully applied to the synthesis of (-)-monomorine. More recently, this strategy has also been utilized in the syntheses of both of the enantiomers of cispyrrolidine 225H and (+)-gephyrotoxin 287C.

Rôle des récepteurs aux cannabinoïdes 1 (CB1R) du tissu adipeux sur la lipolyse et conséquences sur le métabolisme glucido-lipidique de la souris.L’obésité s’accompagne d’une dérégulation de la lipolyse responsable d’une libération excessive d’Acides Gras Libres (AGL) qui sont des acteurs majeurs dans la mise en place de la résistance périphérique à l’insuline. En parallèle, il est maintenant bien établi qu’au cours de l’obésité, une altération de l’activité du Système EndoCannabinoïde (SEC) dans plusieurs tissus métaboliques est observée. S’il est bien décrit que l’hyperactivation de ce système au sein du Tissu Adipeux (TA) favorise son expansion, les conséquences sur la lipolyse adipocytaire restent à déterminer.Ces travaux de thèse ont pour objectif principal de préciser le rôle du SEC dans la régulation de la lipolyse. Pour cela, l’AEA, un agoniste des récepteurs aux cannabinoïdes 1 (CB1R) et le JZL195, un inhibiteur des enzymes de dégradation des endocannabinoïdes, ont été utilisés in vivo chez la souris et in vitro sur un modèle d’explants pour augmenter le tonus endocannabinoïde dans le TA et en mesurer les conséquences sur l’activité lipolytique. Ensuite, les effets du blocage du SEC sur la lipolyse ont été étudiés chez la souris obèse par l’utilisation d’un antagoniste spécifique des CB1R, le Rimonabant.Ces travaux montrent que l’activation du SEC adipocytaire dans des conditions d’insulinémie élevée (période postprandiale) conduit à une altération du signal insulinique et à une perte de son effet antilipolytique favorisant le relargage d’AGL et pouvant, à terme, conduire à des effets délétères sur les tissus périphériques. A l’inverse, lorsque les voies de signalisation à l’insuline sont peu actives comme c’est le cas au cours du jeûne, la stimulation du SEC s’accompagne d’une activation de la voie PI3K/Akt freinant la lipolyse induite par le jeûne et favorisant ainsi le stockage des lipides et l’expansion du TA. Cette situation expérimentale est comparable à celle rencontrée au cours de l’obésité qui est associée à la fois, à une faible activité de la voie PI3K/Akt (résistance à l’insuline) et à une hyperactivation du SEC. Le blocage des CB1R par le Rimonabant chez la souris obèse, conduit à une stimulation importante de la lipolyse qui semble dépendre d’une activation de l’adénylate cyclase. Etant donné qu’un traitement par le Rimonabant s’accompagne également d’une augmentation du catabolisme des acides gras, il est raisonnable de penser que dans ces conditions, les AGL libérés n’exercent pas leurs effets délétères.En conclusion, ces travaux suggèrent que l’activation du SEC participe à l’installation d’une résistance à l’insuline dans le TA qui pourrait, à plus long terme, s’étendre aux tissus périphériques via les effets lipotoxiques des AGL issus de la lipolyse. Au cours de l’obésité, l’association d’une insulinorésistance et d’un tonus endocannabinoïde élevé favoriserait le stockage des lipides et l’expansion de la masse grasse. Au final, le blocage ciblé des CB1R du TA pourrait constituer une piste thérapeutique intéressante pour lutter contre les dérégulations métaboliques associées à l’obésité.Mots clés : Obésité, Insulinorésistance, Système Endocannabinoïde, Tissu Adipeux, Lipolyse, Métabolisme glucido-lipidique / Role of adipose tissue cannabinoid receptor 1 (CB1R) on lipolysis and consequences on lipid and carbohydrate metabolism in miceObesity is accompanied with lipolysis deregulation responsible for excessive Free Fatty Acid (FFA) release, which are key actors in the implementation of peripheral insulin resistance. In parallel, it is now well established that obesity is associated with EndoCannabinoid System (ECS) activity dysfunction in several metabolic tissues. If it is well described that overactivation of this system in the Adipose Tissue (AT) is favourable to its expansion, the consequences on lipolysis remain to be elucidated.The main objective of this thesis work was to precise the role of ECS on lipolysis regulation. To achieve this, AEA, a cannabinoid receptor 1 (CB1R) agonist and JZL195, an inhibitor of the enzymes responsible for the degradation of endocannabinoids, were used, in vivo in mice and in vitro on an explant model, to increase the endocannabinoid tone in the AT and analyse the consequences on lipolytic activity. Then, ECS blockade effect on lipolysis was studied in obese mice by using a specific CB1R antagonist, Rimonabant.This work demonstrates that activation of ECS under high insulinemia condition (postprandial state) alters insulin signalling limiting its antilipolytic effect and increasing FFA release which can ultimately be deleterious for peripheral tissues. Conversely, when insulin signalling pathways are weakly activated, as it is the case during fasting, ECS activation comes with PI3K/Akt activation impeding fasting induced lipolysis and promoting lipid storage and AT expansion. This experimental situation resembles that encountered in obesity which is associated, both with low activity of PI3K/Akt pathway (insulin resistance) and ECS overactivation. CB1R blockade by Rimonabant in obese mice lead to a strong stimulation of lipolysis which seems to be dependent on adenylate cyclase activation. Considering that Rimonabant treatment was also reported to be associated with improved fatty acid catabolism, it can be advanced that FFA released in excess in these conditions, do not have deleterious effects.In conclusion, this work suggests that ECS activation is involved in the onset of AT insulin resistance which ultimately could indirectly affect peripheral tissues via lipolysis derived FFA lipotoxicity. During obesity, the association of insulin resistance and ECS tone elevation would promote lipid storage and AT expansion. Finally, AT CB1R specific blockade could constitute an interesting therapeutic target limiting metabolic deregulations linked to obesity.Key words: Obesity, Insulin Resistance, Endocannabinoid System, Adipose Tissue, Lipolysis, Lipid and carbohydrate metabolism

Analisar a associação recíproca entre fatores de risco cardiometabólico, níveis de adipocitocinas (leptina e adiponectina de alto peso molecular), endocanabinoides (anandamida [AEA] e 2-araquidonoilglicerol [2-AG]), compostos canabimiméticos (N-oleoiletanolamina [OEA] e N-palmitoiletanolamina [PEA]) e polimorfismos em genes codificadores de componentes do sistema endocanabinoide (enzima de degradação de endocanabinoides FAAH [gene FAAH] e receptor endocanabinoide CB1 [gene CNR1]) e do receptor PPAR-&#945; [gene PPARA], em indivíduos com diferentes graus de adiposidade. Duzentos indivíduos, entre 18 e 60 anos, com diferentes graus de índice de massa corporal (IMC) compuseram a amostra, dividida em dois grupos: cem eutróficos (IMC < 25 kg/m2) e 100 obesos (IMC &#8805; 30 kg/m2), com 50 homens e 50 mulheres em cada grupo. Os obesos ficaram assim distribuídos: grau 1, com IMC < 35 kg/m2 (n=54), 27 homens e 27 mulheres; grau 2, com IMC < 40 kg/m2 (n=32), 16 homens e 16 mulheres e grau 3, com IMC &#8805; 40 kg/m2 (n=14), 7 homens e 7 mulheres. Todos os indivíduos foram recrutados entre funcionários, estudantes e residentes do Hospital Universitário Pedro Ernesto, bem como voluntários do quadro da Polícia Militar do Estado do Rio de Janeiro e selecionados com base em amostra de conveniência. Todos foram avaliados por parâmetros antropométricos, determinação da pressão arterial, análises laboratoriais e genotipagem, para determinar seu perfil metabólico, níveis de endocanabinoides e adipocitocinas e rastreamento dos polimorfismos FAAH 385C>A, CNR1 3813A>G e PPARA 484C>G. Foram excluídos do estudo aqueles com história de comorbidades crônicas, doenças inflamatórias agudas, dependência de drogas de qualquer natureza e em uso de medicação nos dez dias anteriores à entrada no estudo. A atividade inflamatória, avaliada pela proteína C reativa ultrassensível (PCRUS), acompanhou o grau de resistência insulínica. Os níveis de PEA se associaram negativamente com a adiposidade visceral e resistência insulínica, sugerindo um melhor perfil metabólico, enquanto que os níveis de 2-AG se associaram positivamente com a PCRUS, apontando para piora nesse perfil. Os polimorfismos estudados não se associaram com o fenótipo obeso ou insulinorresistente. A presença do alelo 3813G no gene CNR1 mostrou associação independente com níveis reduzidos de adiponectina em obesos, sugerindo pior perfil metabólico nesse grupo. A presença do alelo 484G no gene PPARA, associando-se com níveis mais elevados de IMC e LDL-colesterol nos eutróficos pode indicar maior predisposição desses indivíduos para o desenvolvimento de obesidade e dislipidemia aterosclerótica. O genótipo homozigoto AA na posição 385 do gene FAAH e os níveis de PCRUS foram as principais associações, diretas e independentes, com os níveis de AEA, indicando claramente disfunção da enzima de degradação da AEA e, possivelmente, contribuindo para um perfil cardiometabólico mais vulnerável em portadores dessa variante genética. / To analyze the reciprocal association of cardiometabolic risk factors, levels of adipocytokines (leptin and high molecular weight adiponectin), endocannabinoids (anandamide [AEA] and 2-arachidonoylglycerol [2-AG]), cannabimimetic compounds (N-oleoylethanolamine [OEA] and N-palmitoylethanolamine [PEA]) and polymorphisms in genes encoding components of the endocannabinoid system (endocannabinoid degradation enzyme FAAH [FAAH gene] and endocannabinoid receptor CB1 [CNR1 gene]) and the PPAR-&#945; receptor (PPARA gene) in subjects with varying degrees of adiposity. Two hundred individuals between 18 and 60 years with varying degrees of body mass index (BMI) comprised the sample, divided in two groups: one hundred eutrophic (BMI < 25 kg/m2) and 100 obese (BMI &#8805; 30 kg/m2), 50 men and 50 women per group. The obese were distributed as follows: grade 1, with BMI < 35 kg/m2 (n = 54), 27 men and 27 women; grade 2, with BMI between &#8805; 35 and < 40 kg/m2 (n = 32), 16 men and 16 women and grade 3, with BMI &#8805; 40 kg/m2 (n = 14), 7 men and 7 women. All subjects were recruited from staff, students and residents of Pedro Ernesto University Hospital, as well as volunteers from Military Police of Rio de Janeiro State and selected based on a convenience sample. All were evaluated by anthropometric parameters, blood pressure determination, laboratory analysis and genotyping, to determine their metabolic profile, endocannabinoid and adipocytokine levels and investigate the polymorphisms FAAH 385C>A, CNR1 3813G>A and PPARA 484C>G. Those with a history of chronic comorbidities, acute inflammatory diseases, drug addiction of any kind and on medication in the ten days prior to study entry were withdrawn from the study. The inflammatory activity as assessed by high sensitive C reactive protein (hsCRP), accompanied the degree of insulin resistance. The levels of PEA negatively associated with visceral adiposity and insulin resistance, suggesting a better metabolic profile, whereas 2-AG levels were positively associated with hsCRP, pointing to a worse metabolic profile. The polymorphisms studied were not associated with the obese or insulin resistant phenotype. The presence of the allele 3813G in the CNR1 gene was independently associated with reduced levels of adiponectin in obese patients, suggesting a worse metabolic profile in this group. The presence of the allele 484G in the PPARA gene associating with higher levels of BMI and LDL-cholesterol in eutrophics may indicate a predisposition for the development of obesity and atherosclerotic dyslipidemia in these individuals. The homozygous genotype AA in position 385 of the FAAH gene, along with levels of hsCRP, were the main direct and independent associations with AEA levels, clearly indicating dysfunction of the degradation enzyme of AEA and possibly contributing to a more vulnerable cardiometabolic profile in individuals with this variant genotype.